Home Hot keywords

Search Modes

検索結果

Gantenerumab phase 3 discontinue
2019/01/30 — Gantenerumab is also being studied in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial, a global clinical study evaluating ...
2014/12/19 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue SCarlet RoAD (WN25203), a phase III study of investigational ...
2014/12/21 — Swiss drugmaker Roche has announced its plans to discontinue SCarlet RoAD (WN25203), a Phase III study of investigational anti-amyloid ...
2014/12/19 — Roche today announced that it is stopping the Phase 3 SCarlet RoAD trial of its investigational antibody gantenerumab in prodromal ...
S Ostrowitzki 著2017被引用数: 210 — The study was halted early for futility; dosing was discontinued; and the study was unblinded. No differences between groups in the primary ( ...
2019/01/29 — Genentech to Discontinue Phase III CREAD 1 and 2 Clinical Studies of ... including GRADUATE Phase III trials with gantenerumab and the ...
2020/02/10 — On January 30,2019, Roche announced its decision to discontinue CREAD I and CREAD 2 (BN29552 and BN29553) Phase III studies of the ...
Hoffmann La-Roche announced in December 2014 that it was stopping the Phase 3 Scarlet RoAD clinical trial (NCT01224106), after an independent data ...
2018/02/23 — Alzheimer Disease, Drug: Gantenerumab Drug: Placebo, Phase 3 ... Discontinued from study treatment during the double-blind treatment period ...
Alzheimer's Disease, Drug: Gantenerumab Drug: Placebo, Phase 3 ... Part 2 Participants who have been discontinued from the study. Contacts and Locations.

google search trends